Primary series and booster COVID-19 vaccine effectiveness in a cohort of healthcare workers in Albania during a BA.1 and BA.2 variant period, January - May 2022
Listen now
Description
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2023.05.05.23289503v1?rss=1 Authors: Finci, I., Rojas Castro, M. Y., Hasibra, I., Sulo, J., Fico, A., Daja, R., Vasili, A., Kota, M., Preza, I., Muehlemann, B., Drosten, C., Pebody, R., Lafond, K. E., Kissling, E., Katz, M. A., Bino, S. Abstract: Background Healthcare workers (HCWs) have experienced high rates of COVID-19 morbidity and mortality. We estimated COVID-19 two-dose primary series and monovalent booster vaccine effectiveness (VE) against symptomatic SARS-CoV-2 Omicron (BA.1 and BA.2) infection among HCWs in three Albanian hospitals during January-May 2022. Methods Study participants completed weekly symptom questionnaires, underwent PCR testing when symptomatic, and provided quarterly blood samples for serology. We estimated VE using Cox regression models (1-hazard ratio), with vaccination status as the time-varying exposure and unvaccinated HCWs as the reference group, adjusting for potential confounders: age, sex, prior SARS-CoV-2 infection (detected by PCR, rapid-antigen test or serology), and household size. Results At the start of the analysis period, 76% of 1,462 HCWs had received a primary series, 10% had received a booster dose, and 9% were unvaccinated; 1,307 (89%) HCWs had evidence of prior infection. Overall, 86% of primary series and 98% of booster doses received were BNT162b2. The median time interval from the second dose and the booster dose to the start of the analysis period was 289 days (IQR:210-292) and 30 days (IQR:22-46), respectively. VE against symptomatic PCR-confirmed infection was 34% (95%CI: -36;68) for the primary series and 88% (95%CI: 38;98) for the booster. Conclusions Among Albanian HCWs, most of whom had been previously infected, COVID-19 booster dose offered improved VE during a period of Omicron BA.1 and BA.2 circulation. Our findings support promoting booster dose uptake among Albanian HCWs, which, as of January 2023, was only 20%. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
More Episodes
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2023.07.29.23293322v1?rss=1 Authors: Rogier, E., Battle, N., Bakari, C., Seth, M. D., Nace, D., Herman, C., Madebe, R. A., Mandara, C. I., Lyimo, B. M., Giesbrecht, D. J., Popkin-Hall, Z. R., Francis, F., Mbwambo, D., Garimo, I.,...
Published 08/05/23
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2023.07.28.23293338v1?rss=1 Authors: Mushebenge, A. G.-A., Ugbaja, S. C., Mbatha, N. A., Riziki, M. G., Muzumbukilwa, T. W., Kadima, M. G., Kumalo, H. M. Abstract: COVID-19 is a rapidly spreading infectious disease caused by the...
Published 08/05/23